Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | KLK7 | P49862 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6448272 | 1.00 | HSD17B10 (0.43) | HSD17B10SMN1; SMN2USP2RECQLCHRM2 | |
| SCHEMBL17031907 | 0.87 | USP2 (0.41) | HSD17B10SMN1; SMN2USP2RECQLCHRM2 | |
| SCHEMBL1021180 | 0.85 | USP2 (0.40) | HSD17B10SMN1; SMN2USP2RECQLCHRM2 | |
| SCHEMBL6465932 | 0.85 | USP2 (0.40) | HSD17B10SMN1; SMN2USP2RECQLCHRM2 | |
| SCHEMBL8892617 | 0.84 | PTPN1 (0.41) | HSD17B10SMN1; SMN2USP2RECQLCHRM2 | |
| SCHEMBL31716576 | 0.84 | PTPN1 (0.41) | HSD17B10SMN1; SMN2USP2RECQLCHRM2 | |
| SCHEMBL186174 | 0.84 | SMN1; SMN2 (0.50) | HSD17B10SMN1; SMN2USP2RECQLFKBP1A | |
| SCHEMBL154453 | 0.84 | SMN1; SMN2 (0.50) | HSD17B10SMN1; SMN2USP2RECQLFKBP1A | |
| SCHEMBL185522 | 0.84 | SMN1; SMN2 (0.50) | HSD17B10SMN1; SMN2USP2RECQLFKBP1A | |
| SCHEMBL6466005 | 0.83 | SMN1; SMN2 (0.38) | HSD17B10SMN1; SMN2USP2RECQLCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115160306-B | Synthetic method of telithromycin intermediate | 上海皓鸿生物医药科技有限公司 | 2024-03-26 | — | — | CN | disclosed |
| CN-117603152-A | Novel chiral binuclear rhodium complex and preparation method and application thereof | 肇庆学院 | 2024-02-27 | — | — | CN | disclosed |
| CN-115160306-A | Synthetic method of trientine intermediate | 上海皓鸿生物医药科技有限公司 | 2022-10-11 | — | — | CN | disclosed |
| CN-113277991-B | Nitrogen heterocyclic ring amino derivative, preparation method thereof and anti-HIV-1 drug | 中国医学科学院医药生物技术研究所 | 2022-07-12 | — | — | CN | disclosed |
| CN-114044800-A | Aryl, heteroaryl and heterocyclic compounds for the treatment of medical disorders | 艾其林医药公司 | 2022-02-15 | — | — | CN | disclosed |
| CN-113277991-A | Nitrogen heterocyclic ring amino derivative, preparation method thereof and anti-HIV-1 drug | 中国医学科学院医药生物技术研究所 | 2021-08-20 | — | — | CN | disclosed |
| US-20110118305-A1 | COMPOUNDS | SANOFI-AVENTIS (FR) | 2011-05-19 | — | — | US | disclosed |
| EP-1517907-B1 | AZABICYCLO-OCTANE AND NONANE DERIVATIVES WITH DDP-IV INHIBITING ACTIVITY | SANOFI AVENTIS (FR) | 2011-01-12 | — | — | EP | disclosed |
| US-7781455-B2 | Compounds | SANOFI-AVENTIS (FR) | 2010-08-24 | — | — | US | disclosed |
| US-20100160328-A1 | NEW COMPOUNDS USEFUL FOR DPP-IV ENZYME INHIBITION | SANOFI-AVENTIS (FR) | 2010-06-24 | — | — | US | disclosed |
| US-7169932-B2 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses, material for their synthesis | PFIZER INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-20070021354-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | CANAN KOCH STACIE S | 2007-01-25 | — | — | US | disclosed |
| US-20070021354-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | CANAN KOCH STACIE S | 2007-01-25 | — | — | US | disclosed |
| EP-1739082-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | Agouron Pharmaceuticals , Inc. (US) | 2007-01-03 | — | — | EP | disclosed |
| US-20060276487-A1 | New compounds useful for DPP-IV enzyme inhibition | SANOFI-AVENTIS (FR) | 2006-12-07 | — | — | US | disclosed |
| CN-1662530-A | Azabicyclo-octane and nonane derivatives with DPP-IV inhibiting activity | SANOFI SYNTHELABO (FR) | 2005-08-31 | — | — | CN | disclosed |
| US-20050153973-A1 | (4R)-3-(2-{[8-(2-Pyrimidinyl)-8-azabicyclo[3.2.1]oct-3-yl]exo-amino}acetyl)thiazolidine-4-carbonitrile; enzyme inhibitors; diabetes | SANOFI-AVENTIS (FR) | 2005-07-14 | — | — | US | disclosed |
| US-20050107419-A1 | Condensed heterocyclic compounds as calcitonin agonists | SMITHKLINE BEECHAM CORPORATION | 2005-05-19 | — | — | US | disclosed |
| US-6645939-B1 | Very late antigen-4 (VLA) integrin antagonists; antiallergens, antiasthmatics, and antiinflammatory agents; multiple sclerosis, autoimmune disease treatment | MERCK & CO., INC. | 2003-11-11 | — | — | US | disclosed |
| WO-2003076440-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS CALCITONIN AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021354-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | SERPINB1, PEPD, PREP | HSD17B10 962/4885SMN1; SMN2 3932/4885USP2 1237/4885 |
| US-20050107419-A1 | Condensed heterocyclic compounds as calcitonin agonists | CALCRL, CALCR, CALCB | HSD17B10 3475/4885SMN1; SMN2 2254/4885USP2 3490/4885 |
| US-20050153973-A1 | (4R)-3-(2-{[8-(2-Pyrimidinyl)-8-azabicyclo[3.2.1]oct-3-yl]exo-amino}acetyl)thiazolidine-4-carbonitrile; enzyme inhibitors; diabetes | DPP4, DPP8, DPP3 | HSD17B10 2506/4885SMN1; SMN2 4633/4885USP2 1710/4885 |
| US-20110118305-A1 | COMPOUNDS | DPP4, DPP3, DPP8 | HSD17B10 1163/4885SMN1; SMN2 4066/4885USP2 1253/4885 |
| US-20060276487-A1 | New compounds useful for DPP-IV enzyme inhibition | DPP4, DPP7, DPP9 | HSD17B10 428/4885SMN1; SMN2 4097/4885USP2 1401/4885 |
| US-20100160328-A1 | NEW COMPOUNDS USEFUL FOR DPP-IV ENZYME INHIBITION | DPP4, DPP7, DPP9 | HSD17B10 428/4885SMN1; SMN2 4097/4885USP2 1401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.